Production of Omp16 protein fused to the human interleukin 2 in MG1363 toward developing a -based vaccine against brucellosis.

The use of the food-grade bacterium as a new cell factory is a promising alternative expression system for producing a desired protein. The Omp16-IL2 fusion protein antigen was cloned, expressed, and purified in this study. The Omp16-IL2 fusion gene was designed and cloned in pGH plasmid with appropriate restriction sites and subcloned in pAMJ2008 expression vector digested with the same enzymes. The purified recombinant constructed pAMJ-rOmp-IL2 was introduced into subsp. MG1363 by electrotransformation. Finally, the expression and purification of Omp16-IL2 fusion protein was investigated. This study reports the construction of a recombinant expressing the Omp16-IL2 fusion protein as an oral -based vaccine, as compared with commonly used live attenuated vaccines, for future studies against brucellosis.